Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENTATION: Sequential vs Initial Combination Therapy in PAH
NCT06968962Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ambrisentan and tadalafil in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Change in 6-Minute Walk Distance at 12 months. Started May 2025; status: recruiting.
02
Drugs
ambrisentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06968962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968962.